Liftstream is an executive search recruitment company in the life sciences sector
Shire goes hostile on Baxter spin-out Baxalta
Fresh from announcing that the company will acquire Foresight BioTherapeutics for $300m (here), Shire stepped up its ambitions to acquire the recently spun-out Baxalta, which went public earlier this summer (here). Shire originally approached the Baxalta Board of Directors earlier in July about the coming together of the the two companies, since when the Baxalta Board have been ignoring Shire’s advances, which has promoted Shire to go public with its $30.6bn all-stock offer. This hostile move is aimed at drawing out Baxalta shareholders in an attempt to push the Board to enter negotiations. Shire held an investor call today where it laid out its rationale for the deal and articulated how it would allow the company to reach a $20bn revenue company by 2020 and become the undisputed rare disease leader (here).
Shire Eyes Smaller Deal in Shopping Spree
In the recent analyst call for Shire’s Q2 results, CEO Flemming Ornskov suggested that the company was still scouting for acquisitions which would bolster the pipeline in the strategic areas he has set out as priorities. Cognizant that valuations are looking stretched in some areas of biotech, not least rare diseases, the Shire philosophy was seemingly was to look for good value.
M&A Continues to Dominate the Rare Diseases Landscape
Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be in the M&A cross-hairs of both pharmaceutical and big-biotech companies.
13 Life Science Leaders to watch in 2013 – The Verdict!
Authored by Liftstream
Shire expands rare disease reach with Viropharma Purchase
Authored by James Sheppard
Onyx deal signals broader interest in orphan drugs
Authored by Karl Simpson
Shire starts year with flurry of deals
Authored by James Sheppard
13 Life Science Leaders to watch in 2013
Authored by Liftstream
Shire Pharmaceuticals CEO, Angus Russell, announces departure and sucessor
Authored by Karl Simpson